Ratio Therapeutics Funding Round

2/1/2023

Venture Equity

$20,000,000

Series A

The company intends to use the funds to optimize and expand the breadth of its proprietary Trillium and Macropa technology platforms, accelerate the discovery and development of targeted radiotherapies and diagnostics leveraging the platforms' tunable nature to advance programs through clinical-stage development as well as expand the team through hiring and forming new strategic partnerships.

Private & Independent

Biopharmaceutical

77 Sleeper St
Boston, MA 02210
USA

Undisclosed

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics' Trillium� targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.